| Formulary Chapter 2: Cardiovascular system - Full Chapter
|
| Chapter Links... |
 NICE CG107: Hypertension in pregnancy: diagnosis and management |
| NICE CG108: Chronic heart failure in adults: management |
| NICE CG126: Stable angina: management |
| NICE CG127: Hypertension in adults: diagnosis and management |
| NICE CG180: Atrial fibrillation: management |
| NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management |
| NICE NG185; Acute coronary syndromes |
| Details... |
| 02.01 |
Positive inotropic drugs |
|
|
Digoxin
(Tablets)
|
Formulary
|
Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation
Take special care in elderly who may be more susceptible to digitalis toxicity
|
NICE CG180: Atrial fibrillation: management
|
Digoxin
(Elixir)
|
Formulary
|
Use only if still symptomatic despite optimal treatment of HF with atrial fibrillation
Take special care in elderly who may be more susceptible to digitalis toxicity
|
|
|
Digoxin
(injection)
|
Formulary
|
|
|
|
| 02.01.01 |
Cardiac glycosides |
|
|
|
|
| 02.01.01 |
Digoxin-specific antibody |
|
|
Digoxin specific antibody fragments
|
Formulary
|
|
|
|
| 02.01.02 |
Phosphodiesterase type-3 inhibitors |
|
|
Enoximone
|
Formulary
|
|
|
|
| 02.02 |
Diuretics |
|
|
| 02.02.01 |
Thiazides and related diuretics |
|
|
Bendroflumethiazide
(Tablets)
|
Formulary
|
2.5mg dose (higher doses are not indicated in hypertension)
|
NICE Hypertension guidelines
|
Chlortalidone
|
Formulary
|
|
NICE Hypertension guidelines
|
Indapamide
|
Formulary
|
Use 2.5mg standard release tablets only.
|
NICE Hypertension guidelines
|
Indapamide MR
|
Formulary
|
|
|
|
Metolazone
|
Formulary
|
Specialist recommendation
|
MHRA Drug safety Update Jan 2023:Xaqua (metolazone) 5mg tablets: exercise caution when switching patients between metolazone preparations
|
| 02.02.02 |
Loop diuretics |
|
|
Bumetanide
|
Formulary
|
|
|
|
Furosemide
(Tablets, Oral solution, Injection)
|
Formulary
|
|
NICE Chronic heart failure guidelines
|
| 02.02.03 |
Potassium-sparing diuretics and aldosterone antagonists |
|
|
Amiloride Hydrochloride
(Tablets, Oral solution)
|
Formulary
|
|
|
|
| 02.02.03 |
Aldosterone antagonists |
|
|
Spironolactone
(Tablets)
|
Formulary
|
|
NICE CG108: Chronic heart failure in adults: management
|
Eplerenone
|
Formulary
|
|
|
|
| 02.02.04 |
Potassium-sparing diuretics with other diuretics |
|
|
| 02.02.05 |
Osmotic diuretics |
|
|
Mannitol
(Infusion)
|
Formulary
|
Hospital use only
|
|
|
| 02.02.06 |
Mercurial diuretics |
|
|
| 02.02.07 |
Carbonic anhydrase inhibitors |
|
|
Acetazolamide
|
Formulary
|
|
|
|
| 02.02.08 |
Diuretics with potassium |
|
|
| 02.03 |
Anti-arrhythmic drugs |
|
|
| 02.03.01 |
Management of arrhythmias |
|
|
| 02.03.02 |
Drugs for arrhythmias |
|
|
| 02.03.02 |
Supraventricular arrhythmias |
|
|
|
Adenosine (Adenocor®)
|
Formulary
|
Hospital use only
|
|
|
Dronedarone
(Tablets)
|
Formulary
|
In line with NICE TAG TA197
Use current status at Place/Trust
Sandwell
Wolverhampton
ESCA Dronedarone-Wolverhampton only
Walsall
Dudley
ESCA Dronedarone-Dudley only
|
NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
|
| 02.03.02 |
Supraventricular and ventricular arrhythmias |
|
|
|
Amiodarone
(tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
Specialist intiation supported by a RICaD
Amiodarone RICaD-Sandwell only
Atrial fibrillation : Rhythm control should be used when:
symptomatic; under 65's; first time -lone AF; secondary to treated or corrected precipitant with congestive heart failure. Beta-blockers are first line, amiodarone should be used second line where structural heart disease is present
Check thyroid function and liver function every 6 months
Phototoxicity reactions possible - advise use of wide spectrum sunscreen.
Suspect pneumonitis if new or preogressive shortness of breath or cough develops
Following the policy - Items which should not routinely be prescribed in Primary Care. Patients who are established on Amiodarone should continue their prescriptions as normal
The guidance applies to new patients only
Wolverhampton
Walsall
Dudley
|
NICE Atrial fibrillation guidelines
NHS Clinical Commissioners Items which should not routinely be prescribed in primary care: Guidance for CCGs
|
Amiodarone
(injection)
|
Formulary
|
|
|
|
Flecainide
(Injection)
|
Formulary
|
|
|
|
Flecainide
(tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
Initiation under specialist supervision
Contraindicated in heart failure or abnormal left ventricular function
Rhythm control should be used when:
symptomatic; under 65's; first time -lone AF; secondary to treated or corrected precipitant with congestive heart failure. Beta-blockers are first line, flecainide is a second line option when there is no structural heart disease:
Wolverhampton
Walsall
Dudley
|
NICE Atrial fibrillation guidelines
|
Propafenone
|
Formulary
|
|
NICE Atrial fibrillation guidelines
|
| 02.03.02 |
Ventricular arrhythmias |
|
|
|
Mexiletine hydrochloride
|
Formulary
|
|
|
|
Mexiletine unlicensed special
|
Formulary
|
|
|
|
Lidocaine hydrochloride
|
Formulary
|
|
|
|
| 02.04 |
Beta-adrenoceptor blocking drugs |
|
|
Atenolol
|
Formulary
|
|
|
|
Carvedilol
|
Formulary
|
|
|
|
Bisoprolol
|
Formulary
|
|
|
|
Esmolol
(injection)
|
Formulary
|
Hospital use only
|
|
|
Labetalol
(tablets)
|
Formulary
|
|
|
|
Labetolol
(injection 100mg/20ml)
|
Formulary
|
|
|
|
Metoprolol tartrate
(Injection)
|
Formulary
|
|
|
|
Metoprolol tartrate
(Tablets, Modified Release tablets)
|
Formulary
|
|
|
|
Nebivolol
(Tablets)
|
Formulary
|
Follow Optimise Rx advice for new initiations
|
|
|
Propranolol
(Tablets)
|
Formulary
|
|
|
|
Propranolol Hydrochloride (Half-Inderal® LA)
(Modified Release capsules)
|
Formulary
|
|
|
|
Propranolol Hydrochloride (Inderal® LA)
(Modified Release capsules)
|
Formulary
|
|
|
|
Sotalol
|
Formulary
|
Anti-arrhythmic
|
NICE Atrial fibrillation guidelines
|
|
|
|
|
| 02.05 |
Drugs affecting the renin-angiotensin system and some other antihypertensive drugs |
|
|
Ambrisentan
|
Formulary
|
|
|
|
Macitentan (Opsumit®)
|
Formulary
|
NHS England commissioned
|
|
|
Metirosine
|
Formulary
|
|
|
|
Milrinone (Primacor®)
|
Formulary
|
|
|
|
| 02.05.01 |
Vasodilator antihypertensive drugs |
|
|
Hydralazine
(tablets)
|
Formulary
|
|
|
|
Minoxidil (Loniten®)
(Tablets)
|
Formulary
|
Use on specialist advice only
|
|
|
Bosentan
|
Formulary
|
|
|
|
Iloprost
(Injection)
|
Formulary
|
|
|
|
Iloprost nebules (Vantavis®)
|
Formulary
|
NHS England commissioned
|
|
|
Sildenafil
|
Formulary
|
|
|
|
Sodium nitroprusside
|
Formulary
|
Injection (Secondary Care only)
|
|
|
| 02.05.02 |
Centrally acting antihypertensive drugs |
|
|
Clonidine Hydrochloride (Catapres®)
(tablets)
|
Formulary
|
Use only on advice of specialist
|
|
|
Clonidine Liqiud
|
Formulary
|
|
|
|
Methyldopa
(Tablets)
|
Formulary
|
|
|
|
Moxonidine
(Tablets)
|
Formulary
|
|
|
|
| 02.05.03 |
Adrenergic neurone blocking drugs |
|
|
| 02.05.04 |
Alpha-adrenoceptor blocking drugs |
|
|
Doxazosin
|
Formulary
|
|
 Patient Information: Changes to doxazosin prescribing
|
| 02.05.04 |
Phaeochromocytoma |
|
|
Phenoxybenzamine
|
Formulary
|
|
|
|
| 02.05.05 |
Drugs affecting the renin-angiotensin system |
|
|
|
|
|
|
| 02.05.05 |
Heart Failure |
|
|
Sacubitril valsartan (Entresto®)
(film coated tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
Supported by RICaD
Sacubatril valsartan(Entresto) RICaD -Sandwell only
Wolverhampton
Walsall
Dudley
Entresto-Implementation of Entresto (Sacubitril/Valsartan) in Dudley Health Economy
|
NICE TA388:Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
|
| 02.05.05.01 |
Angiotensin-converting enzyme inhibitors (ACE inhibitors) |
|
|
Perindopril erbumine
(Tablets)
|
Formulary
|
DO NOT PRESCRIBE as perindopril arginine salt-Perindopril arginine is Black on the formulary
|
|
|
Ramipril
(Capsules, Tablets)
|
Formulary
|
Prescribe as capsules
|
|
|
Lisinopril
|
Formulary
|
|
|
|
Captopril
(tablets)
|
Formulary
|
For existing patients and Paediatric use
|
|
|
|
|
| 02.05.05.02 |
Angiotensin-II receptor antagonists |
|
|
Candesartan cilexetil
(Tablets)
|
Formulary
|
|
|
|
Irbesartan
(Tablets)
|
Formulary
|
|
|
|
Losartan
(Tablets)
|
Formulary
|
|
|
|
Valsartan
(Capsules)
|
Formulary
|
|
|
|
| 02.05.05.03 |
Renin inhibitors |
|
|
Aliskiren (Rasilez®)
(Tablets)
|
Formulary
|
Guidance for CCGs: Items which should not be routinely prescribed in primary care
|
|
|
| 02.06 |
Nitrates, calcium-channel blockers, and potassium-channel activators |
|
|
Adrenaline / Epinephrine
|
Formulary
|
|
|
|
Atropine
|
Formulary
|
|
|
|
Bivalirudin (Angiox®)
|
Formulary
|
|
NICE CG94: Unstable angina and NSTEMI; early management
|
Cangrelor
|
Formulary
|
|
|
|
Eptifibatide
|
Formulary
|
|
|
|
Nicorandil (Ikorel®)
(Tablets)
|
Formulary
|
Specialist initiation
|
NICE CG126: Stable angina: management
|
Ranolazine (Ranexa®)
(Tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
Supported by RICaD
RICaD Ranolazine-Sandwell only
Wolverhampton
Walsall
Dudley
|
NICE CG126: Stable angina: management
|
Tirofiban (Aggrastat®)
|
Formulary
|
|
|
|
| 02.06 |
Angina |
|
|
|
| 02.06.01 |
Nitrates |
|
|
Glyceryl Trinitrate Injection
|
Formulary
|
Secondary Care use only
|
|
|
Glyceryl Trinitrate Sublingual tablets
|
Formulary
|
|
|
|
Glyceryl Trinitrate Transdermal Patches
|
Formulary
|
|
|
|
Glyceryl Trinitrate 400mcg/ dose Spray
|
Formulary
|
|
|
|
Glyceryl trinitrate buccal
|
Formulary
|
|
|
|
Isosorbide Dinitrate
(Oral)
|
Formulary
|
|
|
|
Isosorbide Mononitrate
(Modified Release Tablets)
|
Formulary
|
Brand prescribe modified release preparations
Follow Optimise Rx advice for new initiations
|
|
|
Isosorbide Mononitrate
(Tablets)
|
Formulary
|
|
|
|
| 02.06.02 |
Calcium-channel blockers |
|
|
Amlodipine
(Tablets)
|
Formulary
|
|
|
|
Diltiazem
|
Formulary
|
|
|
|
Felodipine
(Tablets)
|
Formulary
|
|
|
|
Lercanidipine
|
Formulary
|
|
|
|
Nicardipine (Cardene®)
|
Formulary
|
|
|
|
Nifedipine
|
Formulary
|
|
|
|
Nimodipine (Nimotop®)
(Tablets)
|
Formulary
|
|
|
|
Verapamil
(Tablets, MR tablets/capsules)
|
Formulary
|
Brand prescribe modified release preparations
Follow Optimise Rx advice for new initations
|
UKMI Q&A: What is the evidence for verapamil for prevention of cluster headache?
|
| 02.06.03 |
Other anitanginal drugs |
|
|
Ivabradine
(Tablets)
|
Formulary
|
For use on the advice of a specialist in line with NICE TA267
|
NICE CG126: Stable angina: management
NICE TA267: Ivabradine for treating chronic heart failure
|
| 02.06.04 |
Peripheral vasodilators and related drugs |
|
|
Naftidrofuryl Oxalate
(Capsules)
|
Formulary
|
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
|
| 02.06.04 |
Other preparations used in peripheral vascular disease |
|
|
| 02.07 |
Sympathomimetics |
|
|
Dobutamine
|
Formulary
|
|
|
|
Dopamine
|
Formulary
|
|
|
|
Ephedrine
|
Formulary
|
|
|
|
Isoprenaline
|
Formulary
|
|
|
|
Metaraminol
|
Formulary
|
|
|
|
Midodrine
(Tablets)
|
Formulary
|
Use current status at Place/Trust
Sandwell
ESCA Midodrine- Sandwell only
Wolverhampton
Walsall
Dudley
Unclassified
|
|
|
Noradrenaline / Norepinephrine
|
Formulary
|
|
|
|
Phenylephrine
|
Formulary
|
|
|
|
| 02.07.01 |
Inotropic sympathomimetics |
|
|
| 02.07.02 |
Vasoconstrictor sympathomimetics |
|
|
| 02.07.03 |
Cardiopulmonary resuscitation |
|
|
| 02.08 |
Anticoagulants and protamine |
|
|
Acenocoumarol (Sinthrome®)
(Tablets)
|
Formulary
|
Use on the advice of a specialist only
|
|
|
Edoxaban
|
Formulary
|
|
NICE TA354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
NICE TA355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
|
Apixaban
|
Formulary
|
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options?
NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation)
NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
|
Dabigatran
|
Formulary
|
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options?
NICE TA157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
|
Andexanet
|
Formulary
|
|
|
|
Argatroban (Exembol®)
|
Formulary
|
|
|
|
Bivalirudin (Angiox®)
|
Formulary
|
|
|
|
Danaparoid (Orgaran®)
|
Formulary
|
|
|
|
Epoprostenol (Flolan®)
|
Formulary
|
|
|
|
Fondaparinux (Arixtra®)
(Injection)
|
Formulary
|
Hospital Only
|
|
|
Idarucizumab
|
Formulary
|
|
|
|
Lepirudin
|
Formulary
|
|
|
|
Protamine
|
Formulary
|
|
|
|
Rivaroxaban
|
Formulary
|
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options?
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (March 2015)
|
TauroLock (TauroLock HEP 500®)
|
Formulary
|
|
|
|
Phenindione
(Tablets)
|
Formulary
|
Use on the advice of a specialist only
|
|
|
Warfarin
(Tablets)
|
Formulary
|
Sandwell place
Process for continuing prescribing oral anticoagulants in Primary care-Sandwell only
|
NICE Patient Decision Aid: Atrial Fibrillation: medicines to help reduce your risk of a stroke - what are the options?
UKMI Q&A: Is there an interaction between warfain and proton pump inhibitors?
|
| 02.08.01 |
Parenteral anticoagulants |
|
|
| 02.08.01 |
Heparin |
|
|
Heparin Sodium
(Injection)
|
Formulary
|
|
|
|
| 02.08.01 |
Low molecular weight heparins |
|
|
Dalteparin
|
Formulary
|
Use current Place/Trust Status and local guidelines
Sandwell
 Non formulary
Wolverhampton
Walsall
Non formulary
Dudley
|
|
|
Enoxaparin
(injection)
|
Formulary
|
Use current Place/Trust Status and local guidelines
Sandwell
Single use in suspected DVT
Pregnant women - see URGENT PRESCRIBING OF ENOXAPARIN IN PROPHYLYAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN PREGNANCY
For all other indications
The APC's view is that on clinical grounds, the status for certain indications approved by APC should be Amber Shared Care, supported by an ESCA. These indications are:
- Deep vein thrombosis (including paediatrics)
- Pulmonary embolism (including paediatrics)
- Intolerance/unsuitable for oral anticoagulants
- Certain cancer patients
- Injectable drug users
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED (ESCAs to be developed). This should not prevent individuals in primary care providing initial prescriptions in urgent situations e.g. pregnancy where there is a high thrombotic risk (see guidance linked below).
Wolverhampton
Walsall
Preferred brand-Inhixa and Clexane
Dudley
|
|
|
Tinzaparin
(Injection)
|
Formulary
|
Use current Place/Trust status and local guidelines
Sandwell
Single use in suspected DVT
For all other indications
The APC's view is that on clinical grounds, the status for certain indications approved by APC should be Amber Shared Care, supported by an ESCA. These indications are:
- Deep vein thrombosis (including paediatrics)
- Pulmonary embolism (including paediatrics)
- Intolerance/unsuitable for oral anticoagulants
- Certain cancer patients
- Injectable drug users
- Pregnant women
HOWEVER, until the commissioning arrangements have been agreed to allow safe transfer of patient care, the status will remain RED (ESCAs to be developed). This should not prevent individuals in primary care providing initial prescriptions in urgent situations e.g. pregnancy where there is a high thrombotic risk.
Wolverhampton
Walsall
Dudley
|
NICE NG89: Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism
|
|
|
|
|
| 02.08.01 |
Heparinoids |
|
|
| 02.08.01 |
Hirudins |
|
|
| 02.08.01 |
Heparin flushes |
|
|
| 02.08.01 |
Epoprostenol |
|
|
| 02.08.01 |
Fondaparinux |
|
|
| 02.08.02 |
Oral anticoagulants |
|
|
CoaguChek XS PT Test PST
(Test strips)
|
Formulary
|
Sandwell only -
|
|
|
| 02.08.02 |
Stroke prevention in AF |
|
|
| 02.08.02 |
Atrial Fibrillation |
|
|
|
|
| 02.08.02 |
VTE treatment |
|
|
| 02.08.02 |
VTE prophylaxis in hip/knee surgery |
|
|
| 02.08.02 |
VTE Prophylaxis |
|
|
| 02.08.03 |
Protamine sulphate |
|
|
| 02.09 |
Antiplatelet drugs |
|
|
Aspirin (antiplatelet)
(Dispersible Tablets)
|
First Choice
|
|
TA210: Modified release dipyridamole in combination with aspirin
TA236: Ticagrelor with low dose aspirin for the treatment of acute coronary syndromes
|
Aspirin e/c
|
Second Choice
|
|
|
|
Clopidogrel
(Tablets)
|
Formulary
|
|
CG94: Unstable angina and NSTEMI: The early management of unstable angina and non-ST-segment-elevation myocardial infarction
TA210: clopidogrel and m/r dipyridamole in the prevention of occlusive vascular events
TA80: Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome
|
Dipyridamole MR (Persantin Retard®)
(Capsules)
|
Formulary
|
With specialist initiation
|
|
|
Dipyridamole
(Tablets)
|
Formulary
|
With specialist initiation
|
|
|
Prasugrel (Efient®)
(Tablets)
|
Formulary
|
In line with NICE
|
NICE TA182: Prasugrel for the treatment of acute coronary syndromes with percutaneous cornonary intervention
NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes
|
Ticagrelor (Brilique®)
(Tablets)
|
Formulary
|
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
|
Tirofiban (Aggrastat®)
|
Formulary
|
|
|
|
|
|
|
|
|
|
|
|
| 02.10 |
Stable angina, acute coronary syndromes, and fibrinolysis |
|
|
Alteplase
|
Formulary
|
Hospital only drug
|
NICE TA264: Alteplase for treating acute ischaemic stroke
|
Reteplase
|
 Restricted
|
Hospital only
|
NICE CG68: Stroke and transient ischaemic attack in over 16s: diagnosis and initial management
|
Streptokinase
|
Formulary
|
Hospial only
|
|
|
Urokinase
|
Formulary
|
Hospital only
|
NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
|
|
|
| 02.10.01 |
Management of stable angina and acute coronary syndromes |
|
|
| 02.10.02 |
Fibrinolytic drugs |
|
|
| 02.11 |
Antifibrinolytic drugs and haemostatics |
|
|
Aprotinin (Trasylol®)
|
Formulary
|
|
|
|
Etamsylate (Dicynene®)
|
Formulary
|
|
|
|
Human fibrinogen / Human thrombin (Evicel®)
|
Formulary
|
|
|
|
Tenecteplase
|
Formulary
|
Hospital only
|
|
|
Tisseel®
|
Formulary
|
|
|
|
Tranexamic Acid
(5% Mouthwash)
|
Formulary
|
Palliative use only
|
|
|
Tranexamic Acid
(500mg Tablets)
|
Formulary
|
|
|
|
Tranexamic acid 5% mouthwash
|
Formulary
|
|
|
|
Tranexamic Acid Injection
|
Formulary
|
Injection (Secondary Care only)
|
|
|
| 02.11 |
Blood-related products |
|
|
Factor VIIa (Recombinant) (Eptacog alfa (activated))
|
Formulary
|
|
|
|
Fresh Frozen Plasma
|
Formulary
|
|
|
|
Prothrombin complex injection
|
Formulary
|
|
|
|
| 02.12 |
Lipid-regulating drugs |
|
|
Alirocumab (Praluent®)
|
Formulary
|
In line with NICE.
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
|
Bempedoic acid
|
Formulary
|
|
|
|
Evolocumab (Repatha®)
|
Formulary
|
In line with NICE.
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
|
Inclisiran (Leqvio® )
|
Formulary
|
Inclisiran is covered by NICE TA 733.
|
Inclisiran dosing and administration guide
BCWB ICS CVD CLN Position Statement: Inclisiran (Leqvio). Approved 09/02/2022
Medicines Optimisation Pack for INCLISIRAN
Letter to accompany Inclisiran Medicines Optimisation pack October 2021
NICE TA733: Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia
Procurement guide Inclisiran
RCGP- BMA (December 2021): Information on the proposals for the prescription of inclisiran in primary care settings
|
Volanesorsen
|
Formulary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 02.12 |
Bile acid sequestrants |
|
|
Colesevelam (Cholestagel®)
|
Formulary
|
|
|
|
Colestipol (Colestid®)
|
Formulary
|
|
|
|
Colestyramine
(Sachets)
|
Formulary
|
|
|
|
| 02.12 |
Ezetimibe |
|
|
Ezetimibe (Ezetrol®)
(Tablets)
|
Formulary
|
In line with NICE.
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
|
| 02.12 |
Fibrates |
|
|
Bezafibrate
|
Formulary
|
Immediate release formulation
Modified release formulation
|
|
|
Fenofibrate
(Tablets, Capsules)
|
Formulary
|
|
|
|
| 02.12 |
Statins |
|
|
Atorvastatin
(Tablets)
|
Formulary
|
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
|
Pravastatin
(Tablets)
|
Formulary
|
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
|
Rosuvastatin
(Tablets)
|
Formulary
|
Restricted to patients unable to tolerate other low cost generic statins.
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
|
Simvastatin
(Tablets)
|
Formulary
|
|
CG181:Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
|
| 02.12 |
Nicotinic acid group |
|
|
| 02.12 |
Omega-3 fatty acid compounds |
|
|
Icosapent ethyl
|
Formulary
|
|
NICE TA805 :Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides
|
| 02.12 |
PCSK9 inhibitors |
|
|
| 02.12 |
Other lipid modifying agents |
|
|
Bempedoic acid with ezetimibe (Nustendi®)
(Tablets)
|
Formulary
|
In line with NICE
|
NICE TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia
|
| 02.13 |
Local sclerosants |
|
|
Sodium Tetradecyl Sulphate (Fibro-Vein®)
|
Formulary
|
|
|
|
| 02.14 |
Patent Ductus Arteriosus |
|
|
Alprostadil
|
Formulary
|
|
|
|
Dinoprostone (Prostin E2®)
|
Formulary
|
|
|
|
Ibuprofen (Pedea®)
(Injection)
|
Formulary
|
|
|
|
Indometacin (Indocid PDA®)
|
Formulary
|
|
|
|
| .... |
| Non Formulary Items |
Abciximab
|
Non Formulary
|
|
|
|
Acebutolol (Sectral®)
|
Non Formulary
|
|
|
|
Acipimox
|
Non Formulary
|
|
|
|
Acipimox (Olbetam®)
|
Non Formulary
|
|
|
|
Amiloride with bumetanide
|
Non Formulary
|
|
|
|
Amlodipine and Valsartan (Exforge®)
|
Non Formulary
|
|
|
|
Antithrombin III (Kybemin®)
|
Non Formulary
|
|
|
|
Aspirin (Flamasacard®)
|
Non Formulary
|
|
|
|
Aspirin (antiplatelet) (Angettes® 75)
|
Non Formulary
|
|
|
|
Aspirin (antiplatelet) (Caprin®)
|
Non Formulary
|
|
|
|
Aspirin (antiplatelet) (Nu-Seals® Aspirin)
|
Non Formulary
|
|
|
|
Atenolol and Co-amilozide (Kalten®)
|
Non Formulary
|
|
|
|
Atenolol and Nifedipine
|
Non Formulary
|
|
|
|
Atenolol and Nifedipine (Tenif®)
|
Non Formulary
|
|
|
|
Atenolol with nifedipine
|
Non Formulary
|
|
|
|
Azilsartan
|
Non Formulary
|
|
|
|
Bemiparin
|
Non Formulary
|
|
|
|
Burinex A®
|
Non Formulary
|
|
|
|
Burinex K®
|
Non Formulary
|
|
|
|
Canusal®
|
Non Formulary
|
|
|
|
Captopril and Hydrochlorothiazide (Capozide®)
|
Non Formulary
|
|
|
|
Captopril and Hydrochlorothiazide (Co-zidocapt®)
|
Non Formulary
|
|
|
|
Celiprolol Hydrochloride
|
Non Formulary
|
|
|
|
Centyl K®
|
Non Formulary
|
|
|
|
Chlorothiazide
|
Non Formulary
|
|
|
|
Cilazapril (Vascace®)
|
Non Formulary
|
|
|
|
Cilostazol (Pletal®)
|
Non Formulary
|
|
|
|
Ciprofibrate
|
Non Formulary
|
|
|
|
Clopidogrel (Grepid®)
|
Non Formulary
|
|
|
|
Clopidogrel 300mg (Plavix)
|
Non Formulary
|
|
|
|
Co-amilofruse (furosemide and amiloride)
(Tablets)
|
Non Formulary
|
Combination products should be avoided, unless compliance is an issue |
|
|
Co-amilozide
|
Non Formulary
|
|
|
|
Co-flumactone
|
Non Formulary
|
|
|
|
Colestyramine (Questran®, Questran® Light)
|
Non Formulary
|
|
|
|
Co-tenidone (atenolol and chlortalidone)
|
Non Formulary
|
|
|
|
Co-triamterzide
|
Non Formulary
|
|
|
|
Cozaar- Comp®
|
Non Formulary
|
|
|
|
Cyclopenthiazide (Navidrex®)
|
Non Formulary
|
|
|
|
Diamorphine
|
Non Formulary
|
|
|
|
Digitoxin
|
Non Formulary
|
|
|
|
Dipyridamole (Persantin®)
(Injection)
|
Non Formulary
|
|
|
|
Dipyridamole and Aspirin (Asasantin® Retard)
(Capsules)
|
Non Formulary
|
|
|
|
Disopyramide
(Injection)
|
Non Formulary
|
|
|
|
Disopyramide
(capsules)
|
Non Formulary
|
|
|
|
Disopyramide
|
Non Formulary
|
|
|
|
Disopyramide
(injection)
|
Non Formulary
|
|
|
|
Diumide-K Continus®
|
Non Formulary
|
|
|
|
Dopexamine
|
Non Formulary
|
|
|
|
Drotrecogin Alfa (Activated) (Xigris®)
|
Non Formulary
|
|
|
|
Dyazide®
|
Non Formulary
|
|
|
|
Emicizumab
|
Non Formulary
|
|
|
|
Enalapril
(tablets)
|
Non Formulary
|
For existing patients only |
|
|
Enalapril Meleate and Hydrochlorothiazide (Innozide®)
|
Non Formulary
|
|
|
|
Ephedrine
|
Non Formulary
|
|
|
|
Epoprostenol (Flolan®)
|
Non Formulary
|
|
|
|
Eprosartan (Teveten®)
|
Non Formulary
|
|
|
|
Ethanolamine Oleate
|
Non Formulary
|
|
|
|
Factor IX Fraction, Dried
|
Non Formulary
|
|
|
|
Factor VIIa (Recombinant) (Novo 7®)
|
Non Formulary
|
|
|
|
Factor VIII Fraction, Dried
|
Non Formulary
|
|
|
|
Factor VIII Inhibitor Bypassing Fraction
|
Non Formulary
|
|
|
|
Factor XIII Fraction, Dried
|
Non Formulary
|
|
|
|
Fluvastatin
(Capsules)
|
Non Formulary
|
|
CG181: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease
|
Fluvastatin (Lescol® XL)
|
Non Formulary
|
|
|
|
Fluvastatin m/r
|
Non Formulary
|
|
|
|
Fosinopril Sodium
|
Non Formulary
|
|
|
|
Fresh Frozen Plasma
|
Non Formulary
|
|
|
|
Frusene®
|
Non Formulary
|
|
|
|
Furosemide with triamterene
|
Non Formulary
|
|
|
|
Gemfibrozil
|
Non Formulary
|
|
|
|
Gemifibrozil
|
Non Formulary
|
|
|
|
Gemifibrozil (Lopid®)
|
Non Formulary
|
|
|
|
Guanethidine Monosulphate
|
Non Formulary
|
|
|
|
Heparin
|
Non Formulary
|
|
|
|
Hepsal®
|
Non Formulary
|
|
|
|
Hydralazine Hydrochloride (Apresoline®)
|
Non Formulary
|
|
|
|
Hydrochlorothiazide
|
Non Formulary
|
|
|
|
Imidapril Hydrochloride (Tanatril®)
|
Non Formulary
|
|
|
|
Indapamide (Natrilix-SR®)
|
Non Formulary
|
|
|
|
Indoramin (Baratol®)
|
Non Formulary
|
|
|
|
Indoramin (Doralese®)
|
Non Formulary
|
|
|
|
Inositol Nicotinate (Hexopal®)
|
Non Formulary
|
|
|
|
Irbesartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Isoprenaline
|
Non Formulary
|
|
|
|
Isradipine (Prescal®)
|
Non Formulary
|
|
|
|
Kalspare®
|
Non Formulary
|
|
|
|
Lacidipine (Motens®)
|
Non Formulary
|
|
|
|
Lasikal®
|
Non Formulary
|
|
|
|
Lasilactone®
|
Non Formulary
|
|
|
|
Lisinopril (Zestril®)
|
Non Formulary
|
|
|
|
Lisinopril and Hydrochlorothiazide (Carace® Plus, Lisicostad®, Zestoretic®)
|
Non Formulary
|
|
|
|
Lomitapide (Lojuxta®)
|
Non Formulary
|
|
|
|
Losartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Moexipril Hydrochloride (Perdix®)
|
Non Formulary
|
|
|
|
Moracizine
|
Non Formulary
|
|
|
|
Moxisylyte (Opilon®)
|
Non Formulary
|
|
|
|
Nadolol
|
Non Formulary
|
Discontinued by manufacturers for commercial reasons (April 2016) |
|
|
Naftidrofuryl Oxalate (Praxilene®)
|
Non Formulary
|
|
|
|
Navispare®
|
Non Formulary
|
|
|
|
Neo-NaClex-K®
|
Non Formulary
|
|
|
|
Nicotinic Acid
|
Non Formulary
|
|
|
|
Nicotinic acid/ laropiprant (Tredaptive ®)
|
Non Formulary
|
|
|
|
Nisoldipine (Syscor® MR)
|
Non Formulary
|
|
|
|
Olmesartan (Sevikar®)
|
Non Formulary
|
|
|
|
Olmesartan with amlodipine
|
Non Formulary
|
|
|
|
Olmesartan with amlodipine and hydrochlorothiazide
|
Non Formulary
|
|
|
|
Olmesartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Omega-3-Acid Ethyl Esters (Omacor®)
(Capsules)
|
Non Formulary
|
|
Patient Information: Changes to omega-3 fatty acids prescribing
UKMI Q&A: Review of evidence dor dyslexia
|
Omega-3-Marine Triglycerides (Maxepa)
(Capsules)
|
Non Formulary
|
|
Patient Information: Changes to omega-3 fatty acids prescribing
|
Oxerutins (Paroven®)
|
Non Formulary
|
|
|
|
Oxprenolol Hydrochloride
|
Non Formulary
|
|
|
|
Oxprenolol Hydrochloride
|
Non Formulary
|
|
|
|
Oxprenolol Hydrochloride (Slow-Trasicor®)
|
Non Formulary
|
|
|
|
Oxprenolol Hydrochloride and Cyclopenthiazide (Trasidrex®)
|
Non Formulary
|
|
|
|
Pentoxifylline (Trental®)
|
Non Formulary
|
|
|
|
Perhexiline
(Tablets)
|
Non Formulary
|
|
|
|
Perhexiline
(tablets)
|
Non Formulary
|
|
|
|
Perindopril
|
Non Formulary
|
|
|
|
Perindopril Arginine (Coversyl® Arginine)
(Tablets)
|
Non Formulary
|
In line with NHS England's Guidance for CCGs: Items which should not routinely be prescribed in primary care (Dec 2017)
Click here to access guidance |
Patient Information: Changes to perindopril arginine prescribing
|
Perindopril arginine with indapamide
|
Non Formulary
|
|
|
|
Phentolamine
|
Non Formulary
|
|
|
|
Phenylephrine
|
Non Formulary
|
|
|
|
Pindolol
|
Non Formulary
|
|
|
|
Pindolol (Visken®)
|
Non Formulary
|
|
|
|
Pindolol and Clopamide (Viskaldix®)
|
Non Formulary
|
|
|
|
Pravastatin Sodium (Lipostat®)
|
Non Formulary
|
|
|
|
Prazosin
|
Non Formulary
|
|
|
|
Prazosin (Hypovase®)
|
Non Formulary
|
|
|
|
Procainamide
|
Non Formulary
|
|
|
|
Propranolol Hydrochloride (Inderal®)
|
Non Formulary
|
|
|
|
Protamine Sulphate
|
Non Formulary
|
|
|
|
Protamine Sulphate (Prosulf®)
|
Non Formulary
|
|
|
|
Protein C Concentrate (Ceprotin®)
|
Non Formulary
|
|
|
|
Quinapril
|
Non Formulary
|
|
|
|
Quinapril and Hydrochlorothiazide
|
Non Formulary
|
|
|
|
Ramipril and Felodipine (Triapin®)
|
Non Formulary
|
|
|
|
Rasitro®
|
Non Formulary
|
|
|
|
Sevikar HCT®
|
Non Formulary
|
|
|
|
Simvastatin (Zocor®)
|
Non Formulary
|
|
|
|
Simvastatin and Ezetimibe (Inegy®)
|
Non Formulary
|
|
|
|
Simvastatin with fenofibrate
|
Non Formulary
|
|
|
|
Sitaxentan Sodium (Thelin®)
|
Non Formulary
|
|
|
|
Sotalol Hydrochloride (Beta-Cardone®)
|
Non Formulary
|
|
|
|
Sotalol Hydrochloride (Sotacor®)
|
Non Formulary
|
|
|
|
Spironolactone with furosemide
|
Non Formulary
|
|
|
|
Tadalafil
|
Non Formulary
|
Non formulary for:
- Lower urinary tract symptoms in benign prostatic hyperplasi |
|
|
Tadalafil (Adcirca®)
|
Non Formulary
|
|
|
|
Telmisartan
|
Non Formulary
|
|
|
|
Telmisartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Terazosin
|
Non Formulary
|
|
|
|
Terazosin (Hytin®)
|
Non Formulary
|
|
|
|
Timolol
|
Non Formulary
|
|
|
|
Timolol Maleate and Bendroflumethiazide (Prestim®)
|
Non Formulary
|
|
|
|
Timolol Maleate and Co-amilozide (Moducren®)
|
Non Formulary
|
|
|
|
Timolol with amiloride and hydrochlorothiazide
|
Non Formulary
|
|
|
|
Timolol with bendroflumethiazide
|
Non Formulary
|
|
|
|
Tolazoline
|
Non Formulary
|
|
|
|
Torasemide
|
Non Formulary
|
|
|
|
Trandolapril (Gopten®)
|
Non Formulary
|
|
|
|
Trandolapril and Verapamil (Tarka®)
|
Non Formulary
|
|
|
|
Tranexamic Acid (Cyklokapron®)
|
Non Formulary
|
|
|
|
Treprostinil
|
Non Formulary
|
|
|
|
Triamterene (Dytac®)
|
Non Formulary
|
|
|
|
Triamterene with chlortalidone
|
Non Formulary
|
|
|
|
Valsartan with hydrochlorothiazide
|
Non Formulary
|
|
|
|
Vernakalant
|
Non Formulary
|
|
|
|
Xipamide (Diurexan®)
|
Non Formulary
|
|
|
|
| |
Key |
|
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
|
